Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy.
Bleomycin has been used as a carrier for several radioisotopes; however, its potential for clinical use has been limited either by the in vivo stability of the complexes or the half-life of the isotope used. The chemical, biological, and radiological properties of 105Rhodium appear to make it an ideal choice for targeted radiotherapy. The synthesis and purification of a hereto unreported 105Rhodium-bleomycin (105Rh-BLM) complex is described. The stability of this complex in plasma is sufficient to allow targeted delivery of the radioisotope. 57Cobalt-bleomycin was studied under identical conditions for comparative purposes. The suitability of 105Rh-BLM for targeted therapy, which appears to be limited by the renal clearance of this agent, is discussed.
Brooks
R C
RC
Institute of Cancer Research and Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK.
Carnochan
P
P
Vollano
J F
JF
Powell
N A
NA
Zweit
J
J
Sosabowski
J K
JK
Martellucci
S
S
Darkes
M C
MC
Fricker
S P
SP
Murrer
B A
BA
D000818:Animals; D001761:Bleomycin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D004355:Drug Stability; D008297:Male; D009374:Neoplasms, Experimental / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D051381:Rats; D012238:Rhodium / Q000627:therapeutic use*; D014018:Tissue Distribution
D011868:Radioisotopes; D001761:Bleomycin; D012238:Rhodium